Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;88(11):4742-4750.
doi: 10.1111/bcp.15384. Epub 2022 May 29.

Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B

Yangang Zhou  1   2 , Ying Li  1   2 , Xubiao Xie  3 , Lei Song  3 , Gongbin Lan  3 , Bao Sun  1   2 , Tiantian Tang  1   2 , Han Yan  1   2 , Bikui Zhang  1   2 , Ping Xu  1   2
Affiliations
Free article

Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B

Yangang Zhou et al. Br J Clin Pharmacol. 2022 Nov.
Free article

Abstract

Background: Toxicity is a major concern related to the clinical use of polymyxin B, and available safety data for renal transplant patients are limited.

Aims: We investigated the safety of polymyxin B and toxicity risk factors in renal transplant patients.

Methods: A prospective study was performed on a group of renal transplant patients who received intravenous polymyxin B between January 2018 and August 2021. Polymyxin B treatment was monitored to evaluate toxicity and risk factors.

Results: A total of 235 courses of polymyxin B were administered to 213 patients. Of these, 121 (51.5%) developed skin hyperpigmentation (SH), 149 (63.4%) developed neurotoxicity and 10 (5.5%) developed acute kidney injury of which 80% was reversible. Risk factors for developing SH included a high total dose by weight (odds ration [OR] 1.31, 95% confidence interval [CI] 1.08-1.60, P = .008) and the presence of neurotoxicity (OR 2.86, 95% CI 1.56-5.26, P = .001). Neurotoxicity manifested during the first 2 days of treatment. Neurotoxicity occurred most commonly in women (OR 3.84, 95% CI 1.82-8.10, P < .0001), and the presence of SH (OR 1.98, 95% CI 1.13-3.46, P = .016) was also an independent risk factor.

Conclusions: Neurotoxicity and SH are the two major adverse effects of polymyxin B in renal transplant patients, which may limit its clinical use.

Keywords: neurotoxicity; polymyxin B; renal transplant patients; safety; skin hyperpigmentation.

PubMed Disclaimer

References

REFERENCES

    1. Velkov T, Thompson PE, Azad MAK, Roberts KD, Bergen PJ. History, Chemistry and antibacterial spectrum. Adv Exp Med Biol. 2019;1145:15-36. doi:10.1007/978-3-030-16373-0_3
    1. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39. doi:10.1002/phar.2209
    1. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy. 2015;35(1):28-33. doi:10.1002/phar.1493
    1. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27. doi:10.1186/cc3995
    1. Nelson BC, Eiras DP, Gomez-Simmonds A, et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother. 2015;59(11):7000-7006. doi:10.1128/AAC.00844-15

Publication types

MeSH terms

LinkOut - more resources